title: [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
abstract: The effect of six months' treatment with bezafibrate (400-600 mg daily) on serum lipids, lipoproteins and apolipoproteins concentrations was investigated in 32 patients with primary hyperlipoproteinemia (HLP) type IIa, IIb and IV. In all types of HLP the reduction of serum cholesterol (CH), triglycerides (TG), very low density lipoprotein (VLDL) fraction and increase in high density lipoprotein (HDL) cholesterol, HDL3-CH and apolipoprotein AI concentrations was observed. In type IIa and IIb HLP low density lipoprotein (LDL) cholesterol and apolipoprotein B levels decreased while in type IV increased. The greatest fall of serum CH concentrations was observed in type IIb while of serum TG level--in type IV. In 15 (46.9%) patients the side effects were noted. They were: abdominal pain, skin rash, myalgia, moderate increase in CPK and aminotransferase activities. Most of there side effects disappeared spontaneously without treatment cessation.
authors.affiliation: Zakładu Epidemiologii i Prewencji Chorób Układu Krazenia Instytutu Kardiologii, Warszawie.
authors.forename: M
authors.initials: M
authors.lastname: Bednarska-Makaruk
authors.forename: A
authors.initials: A
authors.lastname: Kuźmińska
authors.forename: E
authors.initials: E
authors.lastname: Chotkowska
authors.forename: P
authors.initials: P
authors.lastname: Kurjata
authors.forename: M
authors.initials: M
authors.lastname: Polakowska
authors.forename: G
authors.initials: G
authors.lastname: Broda
authors.forename: S
authors.initials: S
authors.lastname: Rywik
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents; D001054:Apolipoproteins A / Q000032:analysis*; D001055:Apolipoproteins B / Q000097:blood*; D001629:Bezafibrate / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*
chemical_list: D000924:Anticholesteremic Agents; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D015243:Cholesterol, VLDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D002784:Cholesterol; D001629:Bezafibrate
vernacular_title: Wpływ bezafibratu na lipidy, lipoproteiny i apoproteiny surowicy u chorych z II i IV typem hiperlipoproteinemii.